However, Ahrendt et al21 reported the opposite results; after analyzing 188 patients with operable NSCLC, they showed that the risk of death was significantly higher in patients with p53 mutations than wild‐type patients. This evidence concerns the gene TP53 and non-small cell lung carcinoma.